Almirall stock holds steady as latest half-year profits improve
Published on 08/17/2026 at 14:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Almirall stock is quoted at 12.62 EUR for ticker ALM on the Bolsa de Madrid as of August 17, 2026, with the shares up 0.33 percent over the last 24 hours according to recent market data.
Half-year results show profit recovery
Recent market coverage of Almirall indicates that the company reported net income of 26.58 million EUR for its latest half-year period, compared with a loss of 5.24 million EUR in the immediately preceding half-year, a swing of 31.82 million EUR that represents a 606.94 percent improvement in the bottom line.
In the same context, Almirall is shown with EBITDA of 198.59 million EUR and an EBITDA margin of 18.72 percent for the latest reporting period, underlining that the business is currently generating positive operating cash flows and double-digit profitability on its revenue base.
Analyst expectations and valuation context
Per a detailed stock overview for Almirall SA that compiles analyst opinions and valuation metrics, the current consensus price range for the shares spans from a low estimate of 12.00 EUR to a high estimate of 17.50 EUR, which places the present 12.62 EUR quote close to the lower end of this range and leaves upside room of 4.88 EUR to the high estimate if the company delivers on expectations.
The same overview notes that Almirall stock currently carries a beta of 0.71 and a volatility measure of 3.25 on its home exchange, suggesting that the shares tend to move less than the broader equity market and may offer somewhat smoother performance for investors compared with more cyclical or higher-beta names.
In addition, the compiled calendar on that page indicates a scheduled earnings release for Almirall on February 23, 2026; while that specific date now lies in the past relative to August 17, 2026, it confirms that the half-year figures highlighted above represent the most recently reported interim financials and therefore form the core of the current fundamental picture.
Dermatology portfolio as a revenue driver
Almirall SA historically generates a large part of its revenue from prescription dermatology products for conditions such as psoriasis, atopic dermatitis, and acne, and the latest EBITDA margin of 18.72 percent indicates that this portfolio continues to support a reasonably efficient operating structure with room for investment in new therapies and geographic expansion.
Within its portfolio, the company focuses on branded treatments marketed to dermatologists and specialist clinics across Europe and other regions, and the swing from a half-year net loss of 5.24 million EUR to a profit of 26.58 million EUR suggests that either revenue growth or improved cost control, or a combination of both, has recently strengthened the economics of these core franchises.
Almirall shares on the Bolsa de Madrid
As of August 17, 2026, the Almirall stock quote of 12.62 EUR on the Bolsa de Madrid, with a daily gain of 0.33 percent, places the shares in the low-teens price band and indicates modest positive momentum in the latest trading session.
The current volatility measure of 3.25 and beta of 0.71 imply that price swings are present but not extreme, so investors tracking Almirall may see the stock as a relatively defensive way to gain exposure to prescription dermatology, especially given the recent improvement in half-year profitability.
Go deeper
Read more on Almirall stock fundamentals and consensus expectations in the detailed market-data overview that compiles the latest half-year EBITDA, margin, net income comparison and the current analyst price range.
Key dermatology product focus
Almirall SA’s strategy centers on developing and commercializing innovative dermatology treatments prescribed in specialist care, and the recent 18.72 percent EBITDA margin suggests that this focus on higher-value, branded therapies is supporting a solid level of operating profitability even as the company invests in research and development for future launches.
Current trading snapshot for Almirall stock
With Almirall stock trading at 12.62 EUR on the Bolsa de Madrid and showing a 0.33 percent gain as of August 17, 2026, the shares currently sit close to the lower end of the 12.00 to 17.50 EUR analyst price range and reflect a market view that balances the improved half-year net income of 26.58 million EUR against the usual execution and regulatory risks in prescription pharmaceuticals.
Fact box
Company: Almirall SA
ISIN: ES0157097017
Ticker: ALM
Exchange: Bolsa de Madrid
Price (as of August 17, 2026): 12.62 EUR
Sector / Industry: Pharmaceuticals - Dermatology
